Repligen Co. (NASDAQ:RGEN) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,320 shares of the biotechnology company's stock after selling 4,664 shares during the quarter. California Public Employees Retirement System owned approximately 0.12% of Repligen worth $9,978,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Repligen by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after purchasing an additional 56,723 shares during the period. Conestoga Capital Advisors LLC raised its position in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after acquiring an additional 6,872 shares during the period. New York State Common Retirement Fund raised its position in shares of Repligen by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock worth $83,693,000 after acquiring an additional 14,398 shares during the period. Stephens Investment Management Group LLC boosted its stake in shares of Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after acquiring an additional 37,057 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after acquiring an additional 203,011 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Activity

In other news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on RGEN shares. Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. Finally, Canaccord Genuity Group lifted their target price on shares of Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and an average target price of $178.64.

Repligen Price Performance

RGEN traded up $7.67 during trading on Friday, reaching $122.86. The company's stock had a trading volume of 978,190 shares, compared to its average volume of 702,020. The company has a market cap of $6.90 billion, a price-to-earnings ratio of -240.90, a PEG ratio of 4.54 and a beta of 1.27. The firm has a fifty day simple moving average of $143.12 and a two-hundred day simple moving average of $146.32. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, analysts anticipate that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.